跳至主要内容
临床试验/PER-077-03
PER-077-03已完成未知

CHEMOTHERAPY OF MAINTENANCE IN BREAST CANCER WITHOUT HORMONE RESPONSE

INTERNATIONAL BREAST CANCER STUDY GROUP - IBCSG,0 个研究点目标入组 0 人开始时间: 2004年1月22日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
0 至 0(—)

入选标准

  • Premenopausal or postmenopausal patients with histologically proven primary breast cancer.
  • Estrogen and progesterone receptor status must be known by immunohistochemistry, before randomization, and both must be negative, which is defined as < 10% of the tumor cells positive by immunohistochemical evaluation.

排除标准

  • Patients with T4 carcinoma with ulceration of skin, infiltration of skin.
  • Patients with bilateral malignancies (except in situ carcinoma), or with a suspicious mass in the opposite breast, tmless that mass has been proven by biopsy to be benign.

研究者

发起方
INTERNATIONAL BREAST CANCER STUDY GROUP - IBCSG,

相似试验

尚未招募
不适用
A study on the impact of pharmaceutical care on breast cancer patients
CTRI/2020/07/026688Self funded
已完成
3 期
IBCSG 22-00 Maintenance Chemotherapy in Hormone Non-Responsive Breast CancerAdjuvant Breast CancerCancer - Breast
ACTRN12605000355673Australia and New Zealand Breast Cancer Trials Group1,080
已完成
不适用
Breast cancer aftercare and follow up and programQuality of life and treatment consequences after breast cancerC50Malignant neoplasm of breast
DRKS00028840niversitätsklinikum Würzburg933
已完成
不适用
Database Study on Chemotherapy Regimens for Breast Cancer, Use Patterns of G-CSF Preparations, and Development of Febrile NeutropeniaBreast cancer
JPRN-UMIN000046199Kyowa Kirin Co., Ltd.33,000
进行中(未招募)
不适用
Preoperative treatment of breast cancer with a combination of epirubicin, docetaxel and bevacizumab. A translational trial on molecular markers and functional imaging to predict response early - PROMIXPatients diagnosed with breast cancer who are candidates for preoperative (neoadjuvant) chemotherapy due to localized primary breast cancer including inflammatory breast cancer suitable for primary medical treatment and/or regional lymph node metastases including ipsilateral supraclavicular nodes with breast cancer diagnosis confirmed by histological examination.MedDRA version: 9.1Level: LLTClassification code 10006200Term: Breast cancer stage IIMedDRA version: 9.1Level: LLTClassification code 10006201Term: Breast cancer stage IIIMedDRA version: 9.1Level: LLTClassification code 10021974Term: Inflammatory breast cancer
EUCTR2007-005858-23-SEPROMIX Trial Group200